Stock Idea: FDA Softens
Biogen’s new Alzheimer’s, drug approval has investors pondering whether this is enough of a change in mindset to reshape opinions about gene editing companies. Bets are being placed in the options market.
Biogen’s new Alzheimer’s, drug approval has investors pondering whether this is enough of a change in mindset to reshape opinions about gene editing companies. Bets are being placed in the options market.
We see option activity picking up in our favorite Latin American payment service company. Morgan Stanley analysts expect stronger than expected growth. The chart looks interesting for the stock to run again.
Tesla, the best innovator with first mover advantage in EV space, gets all the attention. It has a lofty multiple while other auto makers were shunned. Recently, new products signal a change.
JPMorgan makes the case for an early stage growth opportunity within an established company: Urban Air Travel.
Animal Health companies are showing strength recently. Four stocks are poised for new highs as demand for products remain elevated, according to Credit Suisse.
A buying opportunity in a medtech company arises as a competitor product pulls out.
SPX gets extremely overbought. Our Core Strategy catches up. A breakout in RUTH is possible.
Two companies compete in a large and growing diabetes market in the US. New technology brings a complementary, yet competitive product to the market that is gaining market share. Is a take over opportunity coming?
We saw massive call buying building today in a low priced semiconductor stock. Call volume was 10x the daily average. This heavy one sided action comes ahead of earnings next week. Pricing strength amid a huge global chip shortage continues to bode well for this stock.
This company has leveraged up in the low interest rate environment. It has also led a green update in its industry. As commodity prices rebound, this deep value play could see huge gains.
This information is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not correspond to your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or transaction matches your interests, investment objectives, investment horizon and acceptable risk level. AVC Adisvory, Inc. and its affiliates are not liable for possible losses in case of making transactions or investing in the financial instruments mentioned in this information, and do not recommend using this information as the only source of information when making an investment decision.